The pathophysiology of fragile X (and what it teaches us about synapses)

Annual Review of Neuroscience

Volumn 35, Issue , 2012, Pages 417-443

  Bhakar, Asha L ^a   D̈olen, G̈ul ^b   Bear, Mark F ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autism; FMRP; long term depression; metabotropic glutamate receptor; mRNA translation

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN; G PROTEIN COUPLED RECEPTOR; GELATINASE B; INITIATION FACTOR 4E; INITIATION FACTOR 4E BINDING PROTEIN; INITIATION FACTOR 4F; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; MICRORNA; MINOCYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE D; RHEB PROTEIN; S6 KINASE; TERNARY COMPLEX FACTOR; TUBERIN;

AUTISM; BRAIN METABOLISM; CARBOXY TERMINAL SEQUENCE; CELL FRACTIONATION; DENDRITE; DENDRITIC SPINE; DISEASE SEVERITY; DNA METHYLATION; ENZYME DEGRADATION; FRAGILE X SYNDROME; GENE INACTIVATION; HIPPOCAMPAL CA1 REGION; HUMAN; INTELLECTUAL IMPAIRMENT; INTRACELLULAR SIGNALING; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; NUCLEAR EXPORT SIGNAL; NUCLEAR LOCALIZATION SIGNAL; OPEN READING FRAME; PHENOTYPE; POINT MUTATION; POLYSOME; POSTTRANSCRIPTIONAL GENE SILENCING; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN RNA BINDING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; RNA TRANSPORT; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SMALL RIBOSOMAL SUBUNIT; TRANSLATION INITIATION; TRINUCLEOTIDE REPEAT; TUBEROUS SCLEROSIS;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; NERVE TISSUE PROTEINS; NEURONAL PLASTICITY; PROTEIN BIOSYNTHESIS; RECEPTORS, METABOTROPIC GLUTAMATE; RNA; SIGNAL TRANSDUCTION; SYNAPSES;

EID: 84862637069     PISSN: 0147006X     EISSN: 15454126     Source Type: Book Series    
DOI: 10.1146/annurev-neuro-060909-153138     Document Type: Review

References (209)

1. Ahn JY, Ye K. 2005. PIKE GTPase signaling and function. Int. J. Biol. Sci. 1:44-50
2. Anderson P, Kedersha N. 2006. RNA granules. J. Cell Biol. 172:803-8
3. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ. 2004. Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J. Neurosci. 24:2648-55 (Pubitemid 38380941)
4. Antar LN, Dictenberg JB, Plociniak M, Afroz R, Bassell GJ. 2005. Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes Brain Behav. 4:350-59 (Pubitemid 41192447)
5. Antar LN, Li C, Zhang H, Carroll RC, Bassell GJ. 2006. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol. Cell Neurosci. 32:37-48 (Pubitemid 43868095)
6. Antion MD, Hou L, Wong H, Hoeffer CA, Klann E. 2008. mGluR-dependent long-term depression is associated with increased phosphorylation of S6 and synthesis of elongation factor 1A but remains expressed in S6K-deficient mice. Mol. Cell. Biol. 28:2996-3007 (Pubitemid 351556531)
7. Aschrafi A, Cunningham BA, Edelman GM, Vanderklish PW. 2005. The fragile X mental retardation protein and group I metabotropic glutamate receptors regulate levels of mRNA granules in brain. Proc. Natl. Acad. Sci. USA 102:2180-85 (Pubitemid 40262032)
8. Ashley C, Wilkinson K, Reines D, Warren S. 1993. FMR1 protein: conserved RNP family domains and selective RNA binding. Science 262:563-66 (Pubitemid 23350668)
9. Auerbach BD, Bear MF. 2010. Loss of the fragile X mental retardation protein decouples metabotropic glutamate receptor dependent priming of long-term potentiation from protein synthesis. J. Neurophysiol. 104:1047-51
10. Auerbach BD, Osterweil EK, Bear MF. 2011. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68
11. Banko JL, Hou L, Poulin F, Sonenberg N, Klann E. 2006. Regulation of eukaryotic initiation factor 4E by converging signaling pathways duringmetabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 26:2167-73 (Pubitemid 44699025)
12. Barbee SA, Estes PS, Cziko AM, Hillebrand J, Luedeman RA, et al. 2006. Staufen-and FMRP-containing neuronal RNPs are structurally and functionally related to somatic P bodies. Neuron 52:997-1009 (Pubitemid 44909400)
13. Bateup HS, Takasaki KT, Saulnier JL, Denefrio CL, Sabatini BL. 2011. Loss of Tsc1 in vivo impairs hippocampal mGluR-LTD and increases excitatory synaptic function. J. Neurosci. 31:8862-69
14. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27:370-77 (Pubitemid 38829251)
15. Bechara EG, Didiot MC, Melko M, Davidovic L, Bensaid M, et al. 2009. A novel function for fragile Xmental retardation protein in translational activation. PLoS Biol. 7:e16
16. Bidinosti M, Ran I, Sanchez-Carbente MR, Martineau Y, Gingras AC, et al. 2010. Postnatal deamidation of 4E-BP2 in brain enhances its associationwith raptor and alters kinetics of excitatory synaptic transmission. Mol. Cell 37:797-808
17. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, et al. 2009. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46:94-102
18. Bishu S, Schmidt KC, Burlin T, Channing M, Conant S, et al. 2008. Regional rates of cerebral protein synthesis measured with L-[1-11C]leucine and PET in conscious, young adult men: normal values, variability, and reproducibility. J. Cereb. Blood Flow Metab. 28:1502-13
19. Bishu S, Schmidt KC, Burlin TV, Channing MA, Horowitz L, et al. 2009. Propofol anesthesia does not alter regional rates of cerebral protein synthesis measured with L-[1-(11)C]leucine and PET in healthy male subjects. J. Cereb. Blood Flow Metab. 29:1035-47
20. Blackwell E, Zhang X, Ceman S. 2010. Arginines of the RGG box regulate FMRP association with polyribosomes and mRNA. Hum. Mol. Genet. 19:1314-23
21. Bolduc FV, Bell K, Cox H, Broadie KS, Tully T. 2008. Excess protein synthesis in Drosophila fragile X mutants impairs long-term memory. Nat. Neurosci. 11:1143-45
22. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, et al. 2001. Microarray identification of FMRPassociated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-87 (Pubitemid 33152783)
23. Callan MA, Cabernard C, Heck J, Luois S, Doe CQ, Zarnescu DC. 2010. Fragile X protein controls neural stem cell proliferation in the Drosophila brain. Hum. Mol. Genet. 19:3068-79
24. Castren M, Tervonen T, Karkkainen V, Heinonen S, Castren E, et al. 2005. Altered differentiation of neural stem cells in fragile X syndrome. Proc. Natl. Acad. Sci. USA 102:17834-39 (Pubitemid 41803583)
25. Caudy AA, Hannon GJ. 2004. Induction and biochemical purification of RNA-induced silencing complex from Drosophila S2 cells. Methods Mol. Biol. 265:59-72
26. Caudy AA, Myers M, Hannon GJ, Hammond SM. 2002. Fragile X-related protein and VIG associate with the RNA interference machinery. Genes Dev. 16:2491-96
27. Ceman S, O'Donnell WT, Reed M, Patton S, Pohl J, Warren ST. 2003. Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum. Mol. Genet. 12:3295-305 (Pubitemid 37541075)
28. Centonze D, Rossi S, Mercaldo V, Napoli I, Ciotti MT, et al. 2008. Abnormal striatal GABA transmission in the mouse model for the fragile X syndrome. Biol. Psychiatry 63:963-73 (Pubitemid 351602272)
29. Chang S, Bray SM, Li Z, Zarnescu DC, He C, et al. 2008. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat. Chem. Biol. 4:256-63 (Pubitemid 351419125)
30. Cheever A, Ceman S. 2009. Phosphorylation of FMRP inhibits association with Dicer. RNA 15:362-66
31. Chen L, Yun SW, Seto J, Liu W, TothM. 2003. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 120:1005-17 (Pubitemid 36969801)
32. Chevere-Torres I, Kaphzan H, Bhattacharya A, Kang A, Maki JM, et al. 2012. Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the DeltaRG mouse model of tuberous sclerosis complex. Neurobiol. Dis. 45(3):1101-10
33. Choi CH, McBride SM, Schoenfeld BP, Liebelt DA, Ferreiro D, et al. 2010. Age-dependent cognitive impairment in a Drosophila fragile X model and its pharmacological rescue. Biogerontology 11:347-62
34. Choi CH, Schoenfeld BP, Bell AJ, Hinchey P, Kollaros M, et al. 2011. Pharmacological reversal of synaptic plasticity deficits in the mouse model of fragile X syndrome by group II mGluR antagonist or lithium treatment. Brain Res. 1380:106-19
35. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. 2005. Prolonged epileptiform discharges induced by altered group Imetabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J. Neurosci. 25:8048-55 (Pubitemid 41254408)
36. Coffee B, Keith K, Albizua I, Malone T, Mowrey J, et al. 2009. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am. J. Hum. Genet. 85:503-14
37. Coffee RL Jr, Williamson AJ, Adkins CM, Gray MC, Page TL, Broadie K. 2011. In vivo neuronal function of the fragile X mental retardation protein is regulated by phosphorylation. Hum. Mol. Genet. doi: 10. 1093/hmg/ddr527
38. Collins SC, Bray SM, Suhl JA, Cutler DJ, Coffee B, et al. 2010. Identification of novel FMR1 variants by massively parallel sequencing in developmentally delayed males. Am. J. Med. Genet. A 152A:2512-20
39. Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F, Khandjian EW. 1997. The fragile Xmental retardation protein is associated with poly(A)+ mRNAin actively translating polyribosomes. Hum. Mol. Genet. 6:1465-72 (Pubitemid 27397022)
40. Costa-Mattioli M, Sossin WS, Klann E, Sonenberg N. 2009. Translational control of long-lasting synaptic plasticity and memory. Neuron 61:10-26
41. Cracco JB, Serrano P, Moskowitz SI, Bergold PJ, Sacktor TC. 2005. Protein synthesis-dependent LTP in isolated dendrites of CA1 pyramidal cells. Hippocampus 15:551-56 (Pubitemid 41149577)
42. Croning MD, Marshall MC, McLaren P, Armstrong JD, Grant SG. 2009. G2Cdb: the Genes to Cognition database. Nucleic Acids Res. 37:D846-51
43. Darnell JC. 2011. Defects in translational regulation contributing to human cognitive and behavioral disease. Curr. Opin. Genet. Dev. 21:465-73
44. Darnell JC, Fraser CE, Mostovetsky O, Stefani G, Jones TA, et al. 2005. Kissing complex RNAs mediate interaction between the fragile-X mental retardation protein KH2 domain and brain polyribosomes. Genes Dev. 19:903-18 (Pubitemid 40548059)
45. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, et al. 2011. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247-61
46. De Boulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, et al. 1993. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat. Genet. 3:31-35 (Pubitemid 23063285)
47. De Diego Otero Y, Severijnen LA, van Cappellen G, Schrier M, Oostra B, Willemsen R. 2002. Transport of fragile X mental retardation protein via granules in neurites of PC12 cells. Mol. Cell. Biol. 22:8332-41 (Pubitemid 35304064)
48. de Vrij FM, Levenga J, van der Linde HC, Koekkoek SK, De Zeeuw CI, et al. 2008. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol. Dis. 31:127-32 (Pubitemid 351822560)
49. Desai NS, Casimiro TM, Gruber SM, Vanderklish PW. 2006. Early postnatal plasticity in neocortex of Fmr1 knockout mice. J. Neurophysiol. 96:1734-45 (Pubitemid 44527431)
50. Devys D, Lutz Y, Rouyer N, Bellocq JP, Mandel JL. 1993. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat. Genet. 4:335-40 (Pubitemid 23231479)
51. DeWire SM, Kim J, Whalen EJ, Ahn S, Chen M, Lefkowitz RJ. 2008. Beta-arrestin-mediated signaling regulates protein synthesis. J. Biol. Chem. 283:10611-20
52. Dictenberg JB, Swanger SA, Antar LN, Singer RH, Bassell GJ. 2008. A direct role for FMRP in activitydependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev. Cell 14:926-39 (Pubitemid 351757204)
53. Didiot MC, Subramanian M, Flatter E, Mandel JL, Moine H. 2009. Cells lacking the fragile X mental retardation protein (FMRP) have normal RISC activity but exhibit altered stress granule assembly. Mol. Biol. Cell 20:428-37
54. Dolen G, Carpenter RL, Ocain TD, Bear MF. 2010. Mechanism-based approaches to treating fragile X. Pharmacol. Ther. 127:78-93
55. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, et al. 2007. Correction of fragile X syndrome in mice. Neuron 56:955-62 (Pubitemid 350251119)
56. Dudek SM, Bowen WD, Bear MF. 1989. Postnatal changes in glutamate stimulated phosphoinositide turnover in rat neocortical synaptoneurosomes. Brain Res. Dev. Brain Res. 47:123-28 (Pubitemid 19131961)
57. Dutch-Belgian Fragile X Consort. 1994. Fmr1 knockout mice: a model to study fragile X mental retardation. Cell 78:23-33
58. Eadie BD, Zhang WN, Boehme F, Gil-Mohapel J, Kainer L, et al. 2009. Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus. Neurobiol. Dis. 36:361-73
59. Eberhart DE, Malter HE, Feng Y, Warren ST. 1996. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet. 5:1083-91 (Pubitemid 26318545)
60. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, et al. 2010. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 65:373-84
61. Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, et al. 2008. Reversal of learning deficits in a Tsc2 +-mouse model of tuberous sclerosis. Nat. Med. 14:843-48
62. FahlingM, Mrowka R, Steege A, Kirschner KM, Benko E, et al. 2009. Translational regulation of the human achaete-scute homologue-1 by fragile X mental retardation protein. J. Biol. Chem. 284:4255-66
63. Feng Y, Absher D, Eberhart DE, Brown V, Malter HE, Warren ST. 1997a. FMRP associates with polyribosomes as an m RNP, and the I304N mutation of severe fragile X syndrome abolishes this association. Mol. Cell 1:109-18 (Pubitemid 127376398)
64. Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM. 1997b. Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J. Neurosci. 17:1539-47 (Pubitemid 27089800)
65. Ferguson SS. 2001. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol. Rev. 53:1-24 (Pubitemid 32173106)
66. Ferraguti F, Baldani-Guerra B, Corsi M, Nakanishi S, Corti C. 1999. Activation of the extracellular signalregulated kinase 2 by metabotropic glutamate receptors. Eur. J. Neurosci. 11:2073-82 (Pubitemid 29240572)
67. Fitzjohn SM, Palmer MJ, May JE, Neeson A, Morris SA, Collingridge GL. 2001. A characterisation of longterm depression induced by metabotropic glutamate receptor activation in the rat hippocampus in vitro. J. Physiol. 537:421-30 (Pubitemid 33130499)
68. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, et al. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: resolution of the Sherman paradox. Cell 67:1047-58 (Pubitemid 121001519)
69. Gabel LA, Won S, Kawai H, McKinney M, Tartakoff AM, Fallon JR. 2004. Visual experience regulates transient expression and dendritic localization of fragileXmental retardation protein. J. Neurosci. 24:10579-83 (Pubitemid 39557630)
70. Gabus C, Mazroui R, Tremblay S, Khandjian EW, Darlix JL. 2004. The fragile X mental retardation protein has nucleic acid chaperone properties. Nucleic Acids Res. 32:2129-37 (Pubitemid 38854768)
71. Gallagher SM, Daly CA, Bear MF, Huber KM. 2004. Extracellular signal-regulated protein kinase activation is required for metabotropic glutamate receptor-dependent long-term depression in hippocampal area CA1. J. Neurosci. 24:4859-64 (Pubitemid 38668210)
72. Gebauer F, Hentze MW. 2004. Molecular mechanisms of translational control. Nat. Rev. Mol. Cell Biol. 5:827-35 (Pubitemid 39336276)
73. Giuffrida R, Musumeci S, D'Antoni S, Bonaccorso CM, Giuffrida-Stella AM, et al. 2005. A reduced number of metabotropic glutamate subtype 5 receptors are associated with constitutive homer proteins in a mouse model of fragile X syndrome. J. Neurosci. 25:8908-16 (Pubitemid 41384459)
74. Godfraind JM, Reyniers E, De Boulle K, D'Hooge R, De Deyn PP, et al. 1996. Long-term potentiation in the hippocampus of fragile X knockout mice. Am. J. Med. Genet. 64:246-51
75. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, et al. 2011. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol. Rev. 64:65-87
76. Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, et al. 2010. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J. Neurosci. 30:10624-38
77. Guo W, Allan AM, Zong R, Zhang L, Johnson EB, et al. 2011. Ablation of FMRP in adult neural stem cells disrupts hippocampus-dependent learning. Nat. Med. 17:559-65
78. Guo W, Murthy AC, Zhang L, Johnson EB, Schaller EG, et al. 2012. Inhibition of GSK3β improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum. Mol. Genet. 21:681-91
79. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. 2012. Fragile x syndrome and targeted treatment trials. Results Probl. Cell Differ. 54:297-335
80. Hampson DR, Adusei DC, Pacey LK. 2011. The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome. Biochem. Pharmacol. 81:1078-86
81. Han JM, Sahin M. 2011. TSC1/TSC2 signaling in the CNS. FEBS Lett. 585:973-80
82. Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey DB Jr, et al. 2006. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am. J. Med. Genet. A 140A:1804-13 (Pubitemid 44330644)
83. Hayashi ML, Rao BS, Seo JS, Choi HS, Dolan BM, et al. 2007. Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice. Proc. Natl. Acad. Sci. USA 104:11489-94 (Pubitemid 47175167)
84. Hays SA, Huber KM, Gibson JR. 2011. Altered neocortical rhythmic activity states in Fmr1 KO mice are due to enhanced mGluR5 signaling and involve changes in excitatory circuitry. J. Neurosci. 31:14223-34
85. Herbert TP, Proud CG. 2007. Regulation of translation elogation and the cotranslational protein target pathway. In Translational Control in Biology and Medicine, ed. MB Mathews, N Sonenberg, JWB Hershey, pp. 601-24. Cold Spring Harbor, NY: Cold Spring Harbor Press
86. Hinds HL, Ashley CT, Sutcliffe JS, Nelson DL, Warren ST, et al. 1993. Tissue-specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome. Nat. Genet. 3:36-43 (Pubitemid 23063286)
87. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. 2006. Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51:441-54 (Pubitemid 44189802)
88. Hou L, Klann E. 2004. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression. J. Neurosci. 24:6352-61 (Pubitemid 38944226)
89. Hsieh H, Boehm J, Sato C, Iwatsubo T, Tomita T, et al. 2006. AMPAR removal underlies Aβ-induced synaptic depression and dendritic spine loss. Neuron 52:831-43 (Pubitemid 44828454)
90. Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ. 2008. Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J. Neurosci. 28:7847-62
91. Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mousemodel of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99:7746-50 (Pubitemid 34568762)
92. Huber KM, Kayser MS, Bear MF. 2000. Role for rapid dendritic protein synthesis in hippocampal mGluRdependent long-term depression. Science 288:1254-57
93. Huber KM, Roder JC, Bear MF. 2001. Chemical induction of mGluR5-and protein synthesis-dependent long-term depression in hippocampal area CA1. J. Neurophysiol. 86:321-5 (Pubitemid 32623237)
94. Iacoangeli A, Rozhdestvensky TS, Dolzhanskaya N, Tournier B, Schutt J, et al. 2008a. On BC1 RNA and the fragile X mental retardation protein. Proc. Natl. Acad. Sci. USA 105:734-39 (Pubitemid 351171777)
95. Iacoangeli A, Rozhdestvensky TS, Dolzhanskaya N, Tournier B, Schutt J, et al. 2008b. Reply to Bagni: on BC1 RNA and the fragile X mental retardation protein. Proc. Natl. Acad. Sci. USA 105:E29 (Pubitemid 351872686)
96. Ishizuka A, Siomi MC, Siomi H. 2002. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev. 16:2497-508
97. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, et al. 2004. Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci. 7:113-17 (Pubitemid 38129786)
98. Johnson EM, Kinoshita Y, Weinreb DB, Wortman MJ, Simon R, et al. 2006. Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J. Neurosci. Res. 83:929-43
99. Kandel ER. 2001. The molecular biology of memory storage: a dialogue between genes and synapses. Science 294:1030-38 (Pubitemid 33041851)
100. Kang H, Schuman EM. 1996. A requirement for local protein synthesis in neurotrophin-induced hippocampal synaptic plasticity. Science 273:1402-6 (Pubitemid 26296531)
101. Kaufmann WE, Abrams MT, Chen W, Reiss AL. 1999. Genotype, molecular phenotype, and cognitive phenotype: correlations in fragile X syndrome. Am. J. Med. Genet. 83:286-95 (Pubitemid 29162630)
102. Kelleher RJ 3rd, Bear MF. 2008. The autistic neuron: troubled translation? Cell 135:401-6
103. Khandjian EW, Corbin F, Woerly S, Rousseau F. 1996. The fragile X mental retardation protein is associated with ribosomes. Nat. Genet. 12:91-93 (Pubitemid 26013158)
104. KhandjianEW, FortinA, Thibodeau A, Tremblay S, Cote F, et al. 1995. Aheterogeneous set of FMR1proteins is widely distributed in mouse tissues and is modulated in cell culture. Hum. Mol. Genet. 4:783-89
105. Kiebler MA, Bassell GJ. 2006. Neuronal RNA granules: movers and makers. Neuron 51:685-90 (Pubitemid 44374907)
106. Kim M, Bellini M, Ceman S. 2009. Fragile X mental retardation protein FMRP binds mRNAs in the nucleus. Mol. Cell. Biol. 29:214-28
107. Kim SH, Markham JA, Weiler IJ, Greenough WT. 2008. Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome. Proc. Natl. Acad. Sci. USA 105:4429-34 (Pubitemid 351754397)
108. Koekkoek SK, Yamaguchi K, Milojkovic BA, Dortland BR, Ruigrok TJ, et al. 2005. Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome. Neuron 47:339-52 (Pubitemid 41073876)
109. Krichevsky AM, Kosik KS. 2001. Neuronal RNA granules: a link between RNA localization and stimulationdependent translation. Neuron 32:683-96 (Pubitemid 33145201)
110. Krueger DD, Bear MF. 2011. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62:411-29
111. Krueger DD, Osterweil EK, Bear MF. 2010. Activation of mGluR5 induces rapid and long-lasting protein kinase D phosphorylation in hippocampal neurons. J. Mol. Neurosci. 42:1-8
112. Lacoux C, Di Marino D, Pilo Boyl P, Zalfa F, Yan B, et al. 2012. BC1-FMRP interaction is modulated by 2-O-methylation: RNA-binding activity of the tudor domain and translational regulation at synapses. Nucleic Acids Res. doi: 10. 1093/nar/gkr1254
113. Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. 2001. Evidence that fragile Xmental retardation protein is a negative regulator of translation. Hum. Mol. Genet. 10:329-38 (Pubitemid 32166544)
114. Lauterborn JC, Rex CS, Kramar E, Chen LY, Pandyarajan V, et al. 2007. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J. Neurosci. 27:10685-94 (Pubitemid 47535868)
115. Lee HY, Ge WP, Huang W, He Y, Wang GX, et al. 2011. Bidirectional regulation of dendritic voltage-gated potassium channels by the fragile X mental retardation protein. Neuron 72:630-42
116. Levenga J, de Vrij FM, Oostra BA, Willemsen R. 2010. Potential therapeutic interventions for fragile X syndrome. Trends Mol. Med. 16:516-27
117. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, et al. 2011. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 42:311-17
118. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. 2001. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res. 29:2276-83 (Pubitemid 32514930)
119. Liu ZH, Huang T, Smith CB. 2011. Lithium reverses increased rates of cerebral protein synthesis in a mouse model of fragile X syndrome. Neurobiol. Dis. 45:1145-52
120. Loesch DZ, Huggins R, Petrovic V, Slater H. 1995. Expansion of the CGG repeat in fragile X in the FMR1 gene depends on the sex of the offspring. Am. J. Hum. Genet. 57:1408-13
121. Lu R, Wang H, Liang Z, Ku L, O'Donnell W T, et al. 2004. The fragile X protein controls microtubuleassociated protein 1B translation and microtubule stability in brain neuron development. Proc. Natl. Acad. Sci. USA 101:15201-6 (Pubitemid 39391742)
122. Lugenbeel KA, Peier AM, Carson NL, Chudley AE, Nelson DL. 1995. Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome. Nat. Genet. 10:483-85
123. Maghsoodi B, Poon MM, Nam CI, Aoto J, Ting P, Chen L. 2008. Retinoic acid regulates RARα-mediated control of translation in dendritic RNA granules during homeostatic synaptic plasticity. Proc. Natl. Acad. Sci. USA 105:16015-20
124. Malter JS, Ray BC, Westmark PR, Westmark CJ. 2010. Fragile X syndrome and Alzheimer's disease: another story about APP and beta-amyloid. Curr. Alzheimer Res. 7:200-6
125. Mao L, Yang L, Arora A, Choe ES, Zhang G, et al. 2005. Role of protein phosphatase 2A in mGluR5-regulated MEK/ERK phosphorylation in neurons. J. Biol. Chem. 280:12602-10
126. Martin JP, Bell J. 1943. A pedigree of mental defect showing sex-linkage. J. Neurol. Psychiatry 6:154-57
127. Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW. 2002. Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. Hum. Mol. Genet. 11:3007-17 (Pubitemid 35414814)
128. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, et al. 2005. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45:753-64 (Pubitemid 40320709)
129. Meredith RM, de Jong R, Mansvelder HD. 2011. Functional rescue of excitatory synaptic transmission in the developing hippocampus in Fmr1-KO mouse. Neurobiol. Dis. 41:104-10
130. Meredith RM, Mansvelder HD. 2010. STDP and mental retardation: dysregulation of dendritic excitability in fragile X syndrome. Front. Synaptic Neurosci. 2:10
131. Michaluk P, Wawrzyniak M, Alot P, SzczotM, Wyrembek P, et al. 2011. Influence of matrix metalloproteinase MMP-9 on dendritic spine morphology. J. Cell Sci. 124:3369-80
132. Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, et al. 2009. Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. Neuropharmacology 56:463-72
133. Mines MA, Jope RS. 2011. Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. Front. Mol. Neurosci. 4:35
134. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. 2007. Dysregulated metabotropic glutamate receptordependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J. Neurosci. 27:5338-48 (Pubitemid 46790157)
135. Muddashetty RS, Nalavadi VC, Gross C, Yao X, Xing L, et al. 2011. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol. Cell 42:673-88
136. Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. 2007. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc. Natl. Acad. Sci. USA 104:15537-42 (Pubitemid 47502952)
137. Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, et al. 2008. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134:1042-54
138. Narayanan U, Nalavadi V, Nakamoto M, Pallas DC, Ceman S, et al. 2007. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J. Neurosci. 27:14349-57
139. Narayanan U, Nalavadi V, Nakamoto M, Thomas G, Ceman S, et al. 2008. S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J. Biol. Chem. 283:18478-82
140. Nicoletti F, Wroblewski JT, Fadda E, Costa E. 1988. Pertussis toxin inhibits signal transduction at a specific metabolotropic glutamate receptor in primary cultures of cerebellar granule cells. Neuropharmacology 27:551-56
141. Nosyreva ED, Huber KM. 2006. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J. Neurophysiol. 95:3291-95
142. Osterweil EK, Krueger DD, Reinhold K, Bear MF. 2010. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J. Neurosci. 30:15616-27
143. Pan L, Broadie KS. 2007. Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A convergently regulate the synaptic ratio of ionotropic glutamate receptor subclasses. J. Neurosci. 27:12378-89 (Pubitemid 350085484)
144. Pan L, Woodruff E 3rd, Liang P, Broadie K. 2008. Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling. Mol. Cell. Neurosci. 37:747-60
145. Park S, Park JM, Kim S, Kim JA, Shepherd JD, et al. 2008. Elongation factor 2 and fragile Xmental retardation protein control the dynamic translation of Arc/Arg3. 1 essential for mGluR-LTD. Neuron 59:70-83 (Pubitemid 351905855)
146. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, et al. 1991. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817-22 (Pubitemid 121001715)
147. Pin JP, Waeber C, Prezeau L, Bockaert J, Heinemann SF. 1992. Alternative splicing generates metabotropic glutamate receptors inducing different patterns of calcium release in Xenopus oocytes. Proc. Natl. Acad. Sci. USA 89:10331-35
148. Plante I, Davidovic L, Ouellet DL, Gobeil LA, Tremblay S, et al. 2006. Dicer-derived microRNAs are utilized by the fragile Xmental retardation protein for assembly on target RNAs. J. Biomed. Biotechnol. 2006:64347
149. Premont RT, Inglese J, Lefkowitz RJ. 1995. Protein kinases that phosphorylate activated G protein-coupled receptors. FASEB J. 9:175-82
150. Qin M, Kang J, Burlin TV, Jiang C, Smith CB. 2005. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J. Neurosci. 25:5087-95 (Pubitemid 40712853)
151. Reiss AL, Dant CC. 2003. The behavioral neurogenetics of fragileXsyndrome: analyzing gene-brain-behavior relationships in child developmental psychopathologies. Dev. Psychopathol. 15:927-68 (Pubitemid 351480023)
152. Repicky S, Broadie K. 2009. Metabotropic glutamate receptor-mediated use-dependent down-regulation of synaptic excitability involves the fragile X mental retardation protein. J. Neurophysiol. 101:672-87
153. Richter JD, SonenbergN. 2005. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477-80 (Pubitemid 40204297)
154. Ronesi JA, Huber KM. 2008. Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J. Neurosci. 28:543-47
155. Rooms L, Kooy RF. 2011. Advances in understanding fragile X syndrome and related disorders. Curr. Opin. Pediatr. 23:601-6
156. Santoro MR, Bray SM, Warren ST. 2011. Molecular mechanisms of fragile x syndrome: a twenty-year perspective. Annu. Rev. Pathol. 7:219-45
157. Scheetz AJ, Nairn AC, Constantine-Paton M. 2000. NMDA receptor-mediated control of protein synthesis at developing synapses. Nat. Neurosci. 3:211-16 (Pubitemid 30140781)
158. Schoepp DD, Conn PJ. 1993. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 14:13-20 (Pubitemid 23034602)
159. Schratt G. 2009. microRNAs at the synapse. Nat. Rev. Neurosci. 10:842-49
160. Shang Y, Wang H, Mercaldo V, Li X, Chen T, Zhuo M. 2009. Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice. J. Neurochem. 111:635-46
161. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, et al. 2010. Dysregulation ofmTOR signaling in fragile X syndrome. J. Neurosci. 30:694-702
162. Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, Mizuno N. 1993. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163:53-57 (Pubitemid 23349393)
163. Siller SS, BroadieK. 2011. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Dis. Model Mech. 4:673-85
164. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. 1993. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74:291-98 (Pubitemid 23221705)
165. Snyder EM, Philpot BD, Huber KM, Dong X, Fallon JR, Bear MF. 2001. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat. Neurosci. 4:1079-85 (Pubitemid 34116552)
166. Stefani G, Fraser CE, Darnell JC, Darnell RB. 2004. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J. Neurosci. 24:7272-76 (Pubitemid 39100696)
167. Stetler A, Winograd C, Sayegh J, Cheever A, Patton E, et al. 2006. Identification and characterization of the methyl arginines in the fragile X mental retardation protein FMRP. Hum. Mol. Genet. 15:87-96 (Pubitemid 43020107)
168. Steward O, Bakker CE, Willems PJ, Oostra BA. 1998. No evidence for disruption of normal patterns ofmRNA localization in dendrites or dendritic transport of recently synthesized mRNA in FMR1 knockout mice, a model for human fragile-X mental retardation syndrome. Neuroreport 9:477-81 (Pubitemid 28109209)
169. Steward O, Levy WB. 1982. Preferential localization of polyribosomes under the base of dendritic spines in granule cells of the dentate gyrus. J. Neurosci. 2:284-91 (Pubitemid 12098607)
170. Su T, Fan HX, Jiang T, Sun WW, Den WY, et al. 2011. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome. Psychopharmacology 215:291-300
171. Suvrathan A, Hoeffer CA, Wong H, Klann E, Chattarji S. 2010. Characterization and reversal of synaptic defects in the amygdala in a mouse model of fragile X syndrome. Proc. Natl. Acad. Sci. 107:11591-96
172. Tamanini F, Meijer N, Verheij C, Willems PJ, Galjaard H, et al. 1996. FMRP is associated to the ribosomes via RNA. Hum. Mol. Genet. 5:809-13 (Pubitemid 26171296)
173. Tauber JM, Vanlandingham PA, Zhang B. 2011. Elevated levels of the vesicular monoamine transporter and a novel repetitive behavior in the Drosophila model of fragile X syndrome. PLoS ONE 6:e27100
174. Tervonen TA, Louhivuori V, Sun X, Hokkanen ME, Kratochwil CF, et al. 2009. Aberrant differentiation of glutamatergic cells in neocortex of mouse model for fragile X syndrome. Neurobiol. Dis. 33:250-59
175. Thomas AM, Bui N, Graham D, Perkins JR, Yuva-Paylor LA, Paylor R. 2011. Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in amousemodel for fragile X syndrome. Behav. Brain Res. 223:310-21
176. Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R. 2012. Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology 219:47-58
177. Todd PK, Mack KJ, Malter JS. 2003. The fragile X mental retardation protein is required for type-I metabotropic glutamate receptor-dependent translation of PSD-95. Proc. Natl. Acad. Sci. USA100:14374-78 (Pubitemid 37499244)
178. Tucker B, Richards RI, Lardelli M. 2006. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum. Mol. Genet. 15:3446-58 (Pubitemid 44811597)
179. Vanderklish PW, Edelman GM. 2002. Dendritic spines elongate after stimulation of group 1 metabotropic glutamate receptors in cultured hippocampal neurons. Proc. Natl. Acad. Sci. USA 99:1639-44 (Pubitemid 34136545)
180. Veloz MF, Buijsen R, Willemsen R, Cupido A, Bosman LW, et al. 2012. The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice. Genes Brain Behav. In press
181. Verkerk AJMH, Pieretti M, Sutcliffe JS, Fu Y-H, Kuhl DPA, et al. 1991. Identification of a gene (FMR-1) containing aCGGrepeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-14 (Pubitemid 121001321)
182. Volk LJ, Pfeiffer BE, Gibson JR, Huber KM. 2007. Multiple Gq-coupled receptors converge on a common protein synthesis-dependent long-term depression that is affected in fragile X syndrome mental retardation. J. Neurosci. 27:11624-34 (Pubitemid 350006892)
183. Wang H, Iacoangeli A, Lin D, Williams K, Denman RB, et al. 2005. Dendritic BC1 RNA in translational control mechanisms. J. Cell Biol. 171:811-21 (Pubitemid 41746583)
184. Wang H, Kim SS, Zhuo M. 2010a. Roles of fragile X mental retardation protein in dopaminergic stimulation-induced synapse-associated protein synthesis and subsequent alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) receptor internalization. J. Biol. Chem. 285:21888-901
185. Wang LW, Berry-Kravis E, Hagerman RJ. 2010b. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 7:264-74
186. Waung MW, Huber KM. 2009. Protein translation in synaptic plasticity: mGluR-LTD, fragile X. Curr. Opin. Neurobiol. 19:319-26
187. Waung MW, Pfeiffer BE, Nosyreva ED, Ronesi JA, Huber KM. 2008. Rapid translation of Arc/Arg3. 1 selectively mediates mGluR-dependent LTD through persistent increases in AMPAR endocytosis rate. Neuron 59:84-97 (Pubitemid 351905854)
188. Weiler IJ, Greenough WT. 1993. Metabotropic glutamate receptors trigger postsynaptic protein synthesis. Proc. Natl. Acad. Sci. USA 90:7168-71 (Pubitemid 23222410)
189. Weiler IJ, Irwin SA, Klintsova AY, Spencer CM, Brazelton AD, et al. 1997. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. USA 94:5395-400 (Pubitemid 27214794)
190. Westmark CJ, Malter JS. 2007. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol. 5:e52
191. Westmark CJ, Westmark PR, Malter JS. 2009. MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Aβ. Int. J. Clin. Exp. Pathol. 3:56-68
192. Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, et al. 2011. βPP/Aβ levels in Fmr1KO mice. PLoS ONE 6:e26549
193. Willemsen R, Oosterwijk JC, Los FJ, Galjaard H, Oostra BA. 1996. Prenatal diagnosis of fragile X syndrome. Lancet 348:967-68
194. Xu XL, Li Y, Wang F, Gao FB. 2008. The steady-state level of the nervous-system-specific microRNA-124a is regulated by dFMR1 in Drosophila. J. Neurosci. 28:11883-89
195. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. 2005. Suppression of twomajor Fragile X syndromemouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053-66 (Pubitemid 41503304)
196. Yang Y, Xu S, Xia L, Wang J, Wen S, et al. 2009. The bantam microRNA is associated with drosophila fragile X mental retardation protein and regulates the fate of germline stem cells. PLoS Genet. 5:e1000444
197. Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS. 2009. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol. 79:632-46
198. Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, et al. 2007. A new function for the fragile Xmental retardation protein in regulation of PSD-95 mRNA stability. Nat. Neurosci. 10:578-87 (Pubitemid 46652449)
199. Zhang J, Hou L, Klann E, NelsonDL. 2009. Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models. J. Neurophysiol. 101:2572-80
200. Zhang L, Alger BE. 2010. Enhanced endocannabinoid signaling elevates neuronal excitability in fragile X syndrome. J. Neurosci. 30:5724-29
201. Zhang Y, Venkitaramani DV, Gladding CM, Kurup P, Molnar E, et al. 2008. The tyrosine phosphatase STEP mediates AMPA receptor endocytosis after metabotropic glutamate receptor stimulation. J. Neurosci. 28:10561-66
202. Zhao MG, Toyoda H, Ko SW, DingHK, Wu LJ, ZhuoM. 2005. Deficits inTrace fear memory and long-term potentiation in a mouse model for fragile X syndrome. J. Neurosci. 25:7385-92 (Pubitemid 41129811)
203. Zhao W, Chuang SC, Bianchi R, Wong RK. 2011. Dual regulation of fragile X mental retardation protein by group I metabotropic glutamate receptors controls translation-dependent epileptogenesis in the hippocampus. J. Neurosci. 31:725-34
204. Zoghbi HY, Bear MF. 2012. Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. doi: 10. 1101/cshperspect. a009886
205. Darnell JC. 2011. Defects in translational regulation contributing to human cognitive and behavioral disease. Curr. Opin. Genet. Dev. 21:465-73
206. FRAXA Res. Found. http://www. fraxa. org
207. Krueger DD, Bear MF. 2011. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62:411-29
208. Levenga J, de Vrij FM, Oostra BA, Willemsen R. 2010. Potential therapeutic interventions for fragile X syndrome. Trends Mol. Med. 16:516-27
209. Natl. Fragile X Found. http://www. fragileX. org